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High levels of pro-inflammatory substances such as cytokines have been described
in the blood and cerebrospinal fluid of schizophrenia patients. Animal models of
schizophrenia show that under certain conditions an immune disturbance during early
life, such as an infection-triggered immune activation, might trigger lifelong increased
immune reactivity. A large epidemiological study clearly demonstrated that severe
infections and autoimmune disorders are risk factors for schizophrenia. Genetic studies
have shown a strong signal for schizophrenia on chromosome 6p22.1, in a region
related to the human leucocyte antigen (HLA) system and other immune functions.
Another line of evidence demonstrates that chronic (dis)stress is associated with
immune activation. The vulnerability-stress-inflammationmodel of schizophrenia includes
the contribution of stress on the basis of increased genetic vulnerability for the
pathogenesis of schizophrenia, because stress may increase pro-inflammatory cytokines
and even contribute to a lasting pro-inflammatory state. Immune alterations influence the
dopaminergic, serotonergic, noradrenergic, and glutamatergic neurotransmission. The
activated immune system in turn activates the enzyme indoleamine 2,3-dioxygenase
(IDO) of the tryptophan/kynurenine metabolism which influences the serotonergic and
glutamatergic neurotransmission via neuroactive metabolites such as kynurenic acid.
The described loss of central nervous system volume and the activation of microglia,
both of which have been clearly demonstrated in neuroimaging studies of schizophrenia
patients, match the assumption of a (low level) inflammatory neurotoxic process.
Further support for the inflammatory hypothesis comes from the therapeutic benefit
of anti-inflammatory medication. Metaanalyses have shown an advantageous effect
of cyclo-oxygenase-2 inhibitors in early stages of schizophrenia. Moreover, intrinsic
anti-inflammatory, and immunomodulatory effects of antipsychotic drugs are known
since a long time. Anti-inflammatory effects of antipsychotics, therapeutic effects of
anti-inflammtory compounds, genetic, biochemical, and immunological findings point to
a major role of inflammation in schizophrenia.
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INTRODUCTION
We humans are constantly being assaulted by infectious agents, noxious chemicals, and physical
traumata. Fortunately, we have evolved a complex process, the inflammatory response, to help fight
and clear infection, remove damaging chemicals, and repair damaged tissue (O’Neill, 2008). The
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harmful effects of inflammation can be observed in many
infectious and autoimmune diseases. The interactions between
environmental factors and genetically encoded components of
the inflammatory response determine whether the outcome will
be health or disease.
As in other sites of the body, inflammation in the central
nervous system (CNS) has a dual role, i.e., it may be
neuroprotective or neurotoxic (Hohlfeld et al., 2007).While acute
inflammation in the CNS (e.g., acute encephalitis) leads to life-
threatening states within hours or days, chronic inflammation
might be associated with impairment over months, years, or a
lifetime.
As an example, multiple sclerosis (MS) is an inflammatory
disease of the CNS that shows a relapsing-remitting course and,
in a certain percentage of patients, also a chronic, progressive
course. Parallels between MS and schizophrenia, which also
often shows a chronic course, have repeatedly been highlighted
as arguments for similar pathogenetic mechanisms in these
disorders (Hanson and Gottesman, 2005).
The concept of “smoldering inflammation” implies that CNS
inflammation drives the disease process in both acute and
chronic stages (Kutzelnigg et al., 2005). While during acute
inflammation the peripheral immune system interacts closely
with the CNS, which is invaded by macrophages and B and T
cells, in chronic processes the immune response in the CNS is
thought to be increasingly secluded from the peripheral immune
system (“compartmentalization” of the inflammatory process;
Meinl et al., 2008; Kerschensteiner et al., 2009). Chronic MS, for
example, is primarily characterized by disseminated activation of
microglial cells.
There are numerous descriptions of an association between
infection, chronic inflammation of the CNS, and schizophrenia
(Anderson et al., 2013). For example, symptoms of schizophrenia
have been described in the encephalitic form ofMS (Felgenhauer,
1990), in viral CNS infection with herpes simplex virus type 1
(HSV-1; Chiveri et al., 2003), HSV-2 (Oommen et al., 1982),
and measles (Hiroshi et al., 2003) and also in autoimmune
processes such as poststreptococcal disorders (Mercadante
et al., 2000; Bechter et al., 2007; Kerbeshian et al., 2007;
Teixeira et al., 2007), lupus erythematodes, and scleroderma
(van Dam, 1991; Müller et al., 1992, 1993; Nikolich-Zugich,
2008).
INFLAMMATORY MECHANISMS IN THE
CNS
Inflammation in the CNS is mediated by pro-inflammatory
cytokines, microglial cells (resident macrophages in the brain),
astrocytes, and invading immune cells such as monocytes,
macrophages, and T or B lymphocytes. Although a well-regulated
inflammatory process is essential for tissue homeostasis and
proper function, an excessive inflammatory response can be
the source of additional injury to host cells. Uncontrolled
inflammation may be the result of either infectious agents (e.g.,
bacteria, viruses) or a reaction to neuronal lesions from traumata,
a genetic defect or environmental toxins.
MICROGLIA AS AN IMPORTANT
CELLULAR BASIS OF INFLAMMATION IN
THE CNS
Microglia comprise ∼15% of the total CNS cells and are the
primary component of the intrinsic immune system in the CNS,
where they provide the first line of defense after injury or disease
and are the principal component of neuroinflammation.
Microglia can be activated in different ways:
(1) A systemic inflammatory challenge triggers microglia
activation, resulting in the release of proinflammatory
cytokines in the CNS, which can mediate “sickness behavior”
(Dantzer, 2001) and othermental states. Microglia play a role
in the synthesis of these central cytokines (van Dam, 1991).
(2) Microglia are “sensitized” or “primed” (Perry, 2007)
by different stimuli, including neurodegeneration
(Cunningham et al., 2005), aging (Godbout and Johnson,
2009), and stress (Sparkman and Johnson, 2008). This
process of sensitization or priming results in the elicitation
of an exaggerated immune response to a weak stimulus. After
priming, a second stimulus, e.g., low systemic inflammation
or stress, may lead to microglia proliferation and increased
production of proinflammatory cytokines by microglia
(Frank et al., 2007). This exaggerated cytokine response
may result in acute changes in behavior by exacerbating or
re-exacerbating an inflammatory pathology in the CNS.
KINDLING AND SENSITIZATION OF THE
IMMUNE RESPONSE: THE BASIS FOR THE
STRESS-INDUCED INFLAMMATORY
RESPONSE IN PSYCHIATRIC DISORDERS
The immune response and the release of cytokines can become
more sensitized to activating stimuli by a kindling process:
the initial immune response, i.e., the release of cytokines
and other mediators of immune activation, is initiated as a
result of exposure to a certain stimulus; thereafter, either re-
exposure to the same stimulus, e.g., stress or infection, is
associated with an increased release of cytokines or a weaker
stimulus is necessary for the same activation process. This
“sensitization” or “kindling” may be due to the memory
function of the acquired immune system (Furukawa et al.,
1998; Sparkman and Johnson, 2008). Stress-associated release
of IL-6 was shown to reactivate (prenatally) conditioned
processes (Zhou et al., 1993). In healthy persons, a second
stimulus (e.g., systemic inflammation, stress) led to immune
activation, associated with cellular proliferation, and increased
production and release of proinflammatory cytokines (Frank
et al., 2007). This mechanism is a key mechanism for triggering
an immune activation and inflammation, e.g., the stress-induced
immune activation leading to psychopathological symptoms. A
sensitization process in the immune system is in accordance
with the view that after an infection during early childhood,
re-infection or another stimulation of the immune system
in later stages of life might be associated with a boosted
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release of sensitized cytokines, resulting in neurotransmitter
disturbances.
Sensitization phenomena play a role in stress-related,
cytokine-induced, neurotransmitter-mediated behavioral
abnormalities, i.e., the cytokine response to a stimulus increases
while the intensity of the stimulus decreases (Sparkman and
Johnson, 2008). In animal experiments, however, cytokines
promote greater neurotransmitter responses when the animals
are re-exposed to the cytokine (Anisman and Merali, 2003), for
example TNF-α (Hayley et al., 2002). In the CNS, the stress-
induced activation and proliferation of microglia may mediate
these cytokine effects (Nair and Bonneau, 2006).
THE VULNERABILITY-STRESS-
INFLAMMATION MODEL OF
SCHIZOPHRENIA
The vulnerability-stress model of psychiatric disorders, first
postulated for schizophrenia more than 30 years ago (Zubin
and Spring, 1977), focuses on the role of physical and
mental stress in triggering a psychotic episode. This model
says that in especially vulnerable individuals (e.g., genetically
vulnerable) stress represents an additional risk for the outbreak
of the schizophrenic disease. An increased vulnerability of the
offspring was shown—in addition to genetic vulnerability—if an
inflammatory response was induced in the mother during the
second trimester of pregnancy or in the offspring during later
stages of CNS development in animal models (Giovanoli et al.,
2013; Green et al., 2014). A recent study, the first large-scale
epidemiological study in psychiatry, showed, however, that severe
infections and autoimmune disorders increase additively the risk
of schizophrenia and schizophrenia spectrum disorders also in
adults (Benros et al., 2011).
The underlying mechanisms of the co-occurrence of stress
and inflammation were studied in animal experiments and stress
was repeatedly shown to be associated with an increase in pro-
inflammatory cytokines (Sparkman and Johnson, 2008).
The specific influence of the inflammatory mechanisms
on neurotransmitter systems in schizophrenia will be
discussed below. Moreover, the modulation of glutamatergic
neurotransmission will be highlighted; glutamate is the
most abundant neurotransmitter in the CNS and differ-
entially involved via cytokine-directed tryptophan/kynurenine
metabolism in schizophrenia, presumably but not exclusively
mediated by NMDA receptors. Besides others, genetic factors of
the kynurenine metabolites play a role (Claes et al., 2011).
THE IMMUNE DYSBALANCE IN
SCHIZOPHRENIA IS ASSOCIATED WITH
CHRONIC INFLAMMATION
Degradation products of inflammatory substances have been
described in schizophrenic brain tissue (Körschenhausen et al.,
1996) and in the CSF of about 50% of schizophrenia patients
(Wildenauer et al., 1991).
Regarding the cytokine pattern in schizophrenia, a blunted
type 1 [e.g., Interferon(IFN)-gamma, Interleukin(IL)-2, soluble
IL-2 receptors] and (compensatory) increased type 2 cytokine
pattern (e.g., IL-6, IL-10) have been repeatedly observed
in unmedicated schizophrenia patients (Müller and Schwarz,
2006). These findings point to an imbalance of the type 1
and type 2 immune responses in schizophrenia. Overviews
on the imbalance in schizophrenia of the type 1 and type
2 and the pro- and anti-inflammatory immune systems as
well as innate immunity, including the monocyte/macrophage
system (Sperner-Unterweger et al., 1992), have recently been
published and indicate that an inflammatory process plays an
important role in the pathophysiology of at least a subgroup of
schizophrenia patients (Potvin et al., 2008; Müller and Schwarz,
2010; Miller et al., 2011). Accordingly, first pilot experiences with
the type 1-stimulating substance interferon-gamma (IFN-γ) as a
therapeutic approach in schizophrenia are encouraging (Grüber
et al., 2014).
THE IMPACT OF INFLAMMATION ON
NEUROTRANSMITTERS IN
SCHIZOPHRENIA
Over the last five decades, research on the neurobiology of
schizophrenia has focused overwhelmingly on disturbances of
dopaminergic neurotransmission (Carlsson, 1988). There is no
doubt that a dysfunction of the dopamine system is involved in
the pathogenesis of schizophrenia, although the mechanism is
not clear and antidopaminergic antipsychotic drugs still show
unsatisfactory therapeutic effects.
IL-1β, which can induce the conversion of rat mesencephalic
progenitor cells into a dopaminergic phenotype (Kabiersch et al.,
1998; Ling et al., 1998; Potter et al., 1999), and IL-6, which
is highly effective in decreasing the survival of fetal brain
serotonergic neurons (Jarskog et al., 1997), seem to have an
important influence on the development of the neurotransmitter
systems involved in schizophrenia, although the specificity of
these cytokines is a matter of discussion. Maternal immune
stimulation during pregnancy was shown to increase the number
of mesencephalic dopaminergic neurons in the fetal brain
(Winter et al., 2009); the increase was probably associated with
a dopaminergic excess in the midbrain (Winter et al., 2009).
Persistent pathogens might be key factors that drive imbalances
of the immune reaction (Nikolich-Zugich, 2008). Nevertheless,
many questions about how immunity and immune pathology
are involved in virus infections remain unanswered (Rouse and
Sehrawat, 2010).
Much evidence seems to indicate that a lack of glutamatergic
neurotransmission, mediated via NMDA antagonism, is a key
mechanism in the pathophysiology of schizophrenia (Müller and
Schwarz, 2007; Genius et al., 2013; Goff, 2015; Howes et al., 2015).
The only NMDA receptor antagonist known to occur naturally
in the human CNS is kynurenic acid (Stone, 1993), one of at
least three neuroactive intermediate products of the kynurenine
pathway. A predominant type 2 immune response inhibits the
enzyme indoleamine 2,3-dioxygenase (IDO), resulting in an
increased production of kynurenic acid in schizophrenia and in
NMDA receptor antagonism (Müller and Schwarz, 2007; Müller
et al., 2011). The recent finding of NMDA receptor antibodies
Frontiers in Neuroscience | www.frontiersin.org 3 October 2015 | Volume 9 | Article 372
Müller et al. Inflammation and immunity in schizophrenia
in about 10% of acute (unmedicated) schizophrenia patients is
especially interesting in this regard (Vincent and Bien, 2008;
Steiner et al., 2013).
Discrepancies in the findings regarding kynurenic acid in
schizophrenia, however, have to be discussed (Kegel et al.,
2014). Elevated kynurenic acid has mainly been described
in the CSF (Erhardt et al., 2001; Linderholm et al., 2012),
in the brains of schizophrenia patients (Schwarcz et al.,
2001; Sathyasaikumar et al., 2011) and in animal models of
schizophrenia (Olsson et al., 2009). However, no increased
kynurenic acid levels were observed in the peripheral blood
of first-episode schizophrenia patients (Condray et al., 2011)
and other groups of schizophrenia patients (Myint et al.,
2011). In a toxoplasma animal model the relationship between
IDO, infection, kynurenine metabolites, and schizophrenia is
exemplified (Notarangelo et al., 2014). Antipsychotic medication,
however, influences kynurenine metabolites and has to be
regarded as an interfering variable (Ceresoli-Borroni et al., 2006;
Condray et al., 2011; Myint et al., 2011).
INFECTION AS A RISK FACTOR
SCHIZOPHRENIA
Prenatal immune activation—infection triggered or not—is an
important risk factor for schizophrenia (Meyer et al., 2011).
Animal models of schizophrenia show that stimulation of the
maternal immune system during pregnancy by viral or bacterial
agents leads to typical (schizophrenia-like) symptoms, i.e., the
disturbed prepulse inhibition in the offspring (Meyer and Feldon,
2009; Meyer et al., 2011).
Evidence for pre- or perinatal exposure to infections as a risk
factor for schizophrenia has not only been obtained from animal
models (Westergaard et al., 1999; Buka et al., 2001). Also in
humans studies of infections as risk factors for schizophrenia
have been performed on several viral disorders (Pearce, 2001;
Brown et al., 2004a; Buka et al., 2008). An increased risk for
schizophrenia in the offspring was observed after respiratory
infections (Brown et al., 2000; Sørensen et al., 2009), genital
infections, and reproductive tract infections (Babulas et al., 2006;
Sørensen et al., 2009). Specifically, women during pregnancy
infected with Toxoplasma gondii were intensely studied as risk
factor for schizophrenia (Brown et al., 2005).
Infections before birth increase the risk for later schizophrenia
(Gattaz et al., 2004; Boksa, 2008; Brown, 2008; Dalman et al.,
2008), as do infections—in particular CNS infections—during
later stages of brain development. Antibody titers against viruses
have been examined in the sera of schizophrenia patients for
many years (Yolken and Torrey, 1995). The results, however,
have been inconsistent, e.g., because interfering factors were not
controlled for. Antibody levels are associated with themedication
state, a finding which partly explains the earlier controversial
results (Leweke et al., 2004). In one of our own studies, higher
titers of different pathogens were found in schizophrenia patients
than in controls, a phenomenon that we called “infectious index”
(Krause et al., 2010).
In humans, increased maternal levels of the proinflammatory
cytokine interleukin-8 (IL-8) during pregnancy were shown
to be associated with an increased risk for schizophrenia in
the offspring, whatever the reason for the increase in IL-8
(Brown et al., 2004b). Moreover, increased maternal IL-8 levels
in pregnancy were also significantly related to decreased brain
volume, i.e., lower volumes of the right posterior cingulum and
left entorhinal cortex and higher volumes of the ventricles in the
schizophrenic offspring (Ellman et al., 2010).
A recent study, the first large-scale epidemiological
study in psychiatry, showed, however, that severe infections
and autoimmune disorders increase additively the risk of
schizophrenia and schizophrenia spectrum disorders (Benros
et al., 2011). This is an important finding, since mostly maternal
infections during pregnancy had been studied before (in
animal models). Infections after birth or during childhood and
adolescence in later schizophrenic diagnosed patients—i.e.,
lifetime infections of the schizophrenia patients—have only
rarely been studied (Benros et al., 2011, 2012). The sensitivity
of the study in recording infections was not high, because
only infections leading to hospital admissions were recorded.
Normally, only extraordinary severe infections lead to a hospital
contact. Therefore, despite the large scale of the study, it may
have clearly identified only the “tip of an iceberg” of risk factors
(Benros et al., 2012).
CNS VOLUME LOSS IN IMAGING
STUDIES—A CONSEQUENCE OF AN
INFLAMMATORY PROCESS?
Gross inflammatory changes have not been found in
neuroimaging or neuropathological studies of schizophrenia.
However, there is no doubt that a decreased CNS volume can
be observed as early as the first episode and a progressive loss
in CNS volume occurs during the further course of the disease
(Chakos et al., 2005; Job et al., 2006; Steen et al., 2006; Gogtay
et al., 2008). Moreover, a relationship was described between
volume loss and an increased genetic risk for a higher production
of the immune marker IL-1β (Meisenzahl et al., 2001); the
relationship between maternal IL-8 levels and CNS volume was
mentioned above (Ellman et al., 2010).
The ligand PK 11195 is used in positron emission tomography
(PET) to estimate microglial activation (Versijpt et al., 2003). In
schizophrenia, an increased expression of PK 11195 was shown
to be a marker of an inflammatory process in the CNS (van
Berckel et al., 2008; Doorduin et al., 2009). Moreover, positive
correlations were also observed between expression of the
microglial activation marker DAA1106 and both schizophrenia
positive symptoms and duration of the disease (Takano et al.,
2010).
CYCLOOXYGENASE-2 (COX-2) INHIBITION
AS AN ANTI-INFLAMMATORY
THERAPEUTIC APPROACH IN
SCHIZOPHRENIA
Modern anti-inflammatory agents have been explored in
schizophrenia. The cyclooxygenase-2 (COX-2) inhibitor
celecoxib was studied in a prospective, randomized, double-
blind study of acute exacerbations of schizophrenia. The
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patients receiving celecoxib add-on to risperidone showed
a statistically significantly better outcome than the patients
receiving risperidone alone; the clinical effects of COX-2
inhibition in schizophrenia were especially pronounced in
cognition (Müller et al., 2005). The efficacy of therapy with a
COX-2 inhibitor seems most pronounced in the first years of
the schizophrenic disease process (Müller, 2010; Müller et al.,
2010). A recent study also demonstrated a beneficial effect
of acetylsalicylic acid in schizophrenic spectrum disorders
(Laan et al., 2010). A meta-analysis of the clinical effects of
non-steroidal anti-inflammatory drugs in schizophrenia revealed
significant effects on schizophrenic total, positive and negative
symptoms (Sommer et al., 2012), while another meta-analysis
found a significant benefit only in schizophrenia patients with a
short duration of disease or in first manifestation schizophrenia
(Nitta et al., 2013).
FURTHER IMMUNE-RELATED
SUBSTANCES IN THE THERAPY OF
SCHIZOPHRENIA
Because of the role of microglia activation in inflammation,
minocycline, an antibiotic and inhibitor of microglia activation,
is an interesting substance for the treatment of schizophrenia.
The improvement of cognition by minocycline has been
described in animal models of schizophrenia (Mizoguchi et al.,
2008) and in two double-blind, placebo-controlled add-on
therapy trials in schizophrenia patients (Levkovitz et al., 2010;
Chaudhry et al., 2012). In clinical studies, positive effects on
schizophrenic negative symptoms were noted as well (Chaudhry
et al., 2012). Case reports documented positive effects of
minocycline on the whole symptom spectrum in schizophrenia
(Ahuja and Carroll, 2007).
Acetylcysteine (ACC) and other substances, including omega-
3 fatty acids, that have anti-inflammatory and other effects
also provide some benefit to schizophrenia patients (overview:
Sommer et al., 2014)
First pilot experiences with cytokine interferon gamma (IFN-
γ), which stimulates the monocytic type 1 immune response,
as a therapeutic approach in schizophrenia are encouraging
(Grüber et al., 2014), although side effects, including unwanted
immune effects, have to be carefully monitored and the results are
only preliminary. On the other hand, such a hypothesis-driven
therapeutic approach opens interesting perspectives for the
development of therapeutic substances based on etiopathology.
METHODOLOGICAL ASPECTS OF THE
RESPONSE TO IMMUNE-BASED THERAPY
IN SCHIZOPHRENIA
The knowledge that schizophrenia is a syndrome and that
different pathological mechanisms may play a role in the
disorder seems to indicate that immune pathology is restricted
to a subgroup of patients. Although several biological markers,
including immune markers, are discussed to reflect subgroups
of schizophrenia, so far no marker is established for an
immune-related schizophrenia. Accordingly, an immune-based
therapeutic approach might be effective only in a subgroup of
patients or, put another way, an immune-based therapy can
be expected to show only a small therapeutic effect in an
unselected group of schizophrenia patients. Another relevant
point is that all clinical studies with immune-based treatment
are add-on studies to an established standard therapy with
antipsychotics. For ethical reasons this design has to be used
until the add-on substance has a proven effect in schizophrenia.
In order to show superiority over an effective antipsychotic in
monotherapy, however, the add-on substance has to have a huge
additional effect before it reaches statistical significance over
placebo and the antipsychotic. In the light of high and increasing
placebo response rates in schizophrenia studies (Rutherford
et al., 2014), anti-inflammatory substances need high effect
sizes to show statistical superiority in double-blind, randomized,
placebo-controlled studies. Moreover, schizophrenia patients
participating in clinical studies, and especially in studies with a
new, unproven therapeutic approach, often show an unfavorable,
sometimes therapy-resistant course of the disorder, i.e., several
of the studies may include a “negative” selection of severely ill
patients.
The above mentioned methodological aspects may explain the
difficulties in showing a convincing effect of anti-inflammatory
drugs in schizophrenia.
CONCLUSION
The possible influence on the pathogenesis of schizophrenia of an
immunological process resulting in inflammation has long been
neglected. Increasing evidence for a role of proinflammatory
cytokines in schizophrenia, the strong influence of pro-
and anti-inflammatory cytokines on tryptophan/kynurenine
metabolism, the related influence of cytokines on glutamatergic
neurotransmission, the results of imaging studies, genetic
findings and, last but not least, the therapeutic effect of anti-
inflammatory drugs all support the view that the recent increased
focus of schizophrenia research on psychoneuroimmunology
and inflammation is justified. On the other hand, one has to
consider that immunological research is susceptible to artifacts,
i.e., interfering variables such as medication, smoking, stress,
sleep, and others play an important role and cannot always be
controlled. This is exemplified by stress, which, according to
the “vulnerability-stress model,” is not only a condition sine
qua non in schizophrenia but is also a confounding factor in
research of the immune system and inflammatory processes.
The situation is similar for neuro-imaging studies: volume loss
might be the result of different pathological processes other than
inflammatory ones. Nevertheless, the results of these studies are
encouraging and further studies should focus on the relationship
between inflammatory markers in the blood and CSF and
volume loss in the CNS. Moreover, the influence of different
disease stages in schizophrenia might also have been neglected.
The syndrome of schizophrenia is discussed to have different
underlying pathological processes. Inflammation, however, also
includes different stages and processes ranging from acute to
chronic inflammation, including an autoimmune process.
These considerations show that although a lot of further
research is necessary to clarify the role of the immune system in
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schizophrenia, recent findings encourage continued emphasis on
this fascinating field.
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